Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients

Lemos, C.; Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G.; Scheffer, G.L.; Straaten, T. van der; ... ; Peters, G.J. (2011)

Article / Letter to editor

• ABCG2
• gefitinib
• lung cancer
• pharmacogenetics
• toxicity

• All authors: Lemos, C.; Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G.; Scheffer, G.L.; Straaten, T. van der; D'Incecco, A.; Falcone, A.; Guchelaar, H.J.; Danesi, R.; Santoro, A.; Giaccone, G.; Tibaldi, C.; Peters, G.J.
• Date: 2011-02-28
• Journal: Pharmacogenomics
• Volume: 12
• Issue: 2
• Pages: 159 - 170
• DOI: doi:10.2217/pgs.10.172